

1. Record Nr.	UNINA9910808718803321
Titolo	Frontiers in clinical drug research - CNS and neurological disorders . Volume 4 // edited by Atta-ur-Rahman
Pubbl/distr/stampa	Sharjah, United Arab Emirates : , : Bentham Science Publishers, , [2016] ©2016
ISBN	1-68108-295-0
Descrizione fisica	1 online resource (385 pages)
Collana	Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Disciplina	616.9948
Soggetti	Central nervous system
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.
Nota di contenuto	Intro -- CONTENTS -- PREFACE -- List of Contributors -- Multiple Sclerosis Drug Therapy: From the Classical Pharmaceutical Down to Cellular and Molecular Approach -- MULTIPLE SCLEROSIS -- Epidemiology, Environmental Agents and Genetics -- Pathogenesis -- Animal Models -- Different Immune System Players on the MS Stage -- T-cells -- B-cells -- Other Immune System Cells and the Innate Immune Response -- Histopathology -- Active Lesions -- Chronic Plaques -- Remyelinated Plaques -- Clinical Features and Diagnostic Criteria -- DISEASE-MODIFYING DRUGS -- Steroids -- Injectable Drugs -- Beta-Interferons -- Glatiramer Acetate -- Oral Drugs -- Teriflunomide -- Dimethyl Fumarate (DMF, BG-12) -- Fingolimod (FTY720) -- Conventional Immunosuppressants -- Cyclophosphamide -- Azathioprine -- Mitoxantrone -- Laquinimod -- Methotrexate -- Biologics (Monoclonal Antibodies) -- Natalizumab -- Alemtuzumab (Campath-1H) -- RECENT EMERGING BIOLOGICAL AND EXPERIMENTAL THERAPEUTICAL APPROACHES -- B-Cells -- Rituximab -- Ocrelizumab and Ofatumumab -- MEDI-551 -- Mast Cells -- Masitinib mesylate -- Cytokines and Chemokines -- Daclizumab -- Tabalumab (LY2127399) -- MOR103 -- Secukinumab -- Tolerogenic Vaccines for MS -- Stem Cells -- Haematopoietic Stem Cells (HSCs) -- Mesenchymal Stem Cells (MSCs) -- Helminths -- Vitamin D -- Remyelination Strategies in MS -- BIIB033 -- rHIgM22 -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES --

Prospective Therapies for Alzheimer Disease: Biomarkers, Clinical Trials and Preclinical Research -- I. INTRODUCTION -- I.1. Background -- I.2. Alzheimer's Disease and the Need for New Drugs -- I.3. The Amyloid Cascade Hypothesis (ACH) -- I.4. Correlation among A and other AD Hallmarks -- I.5. Genetics of AD -- I.5.1. APP -- I.5.2. PSEN1/PSEN2 -- I.5.3. APOE -- I.5.4 . APOJ/CLU. I.5.5. The Role of Genetic Testing in Clinical Care -- II. THE ROLE OF BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIALS ASSESSMENT -- II.1. Biochemical Markers -- II.1.1. Cerebrospinal Fluid Biomarkers -- II.1.2. Blood Biomarkers -- II.2. Imaging-based Biomarkers -- II.2.1. Structural Magnetic Resonance Imaging -- II.2.2. Diffusion Tensor Imaging -- II.2.3. Functional Magnetic Resonance Imaging -- II.2.4. Proton Magnetic Resonance Spectroscopy -- II.2.5. Fluorodeoxyglucose-Positron Emission Tomography -- II.2.6. Amyloid-Positron Emission Tomography -- II.3. The Continuum of AD: Diagnosis and Prognosis -- II.4. Regulatory Framework -- III. PROSPECTIVE THERAPIES -- III.1. Non-immunologic Therapies -- III.1.1. Clinical Trials -- III.1.2. Preclinical Studies -- III.2. Immunotherapy -- III.2.1. Active Immunotherapy -- III.2.2. Passive Immunotherapy -- CONCLUSION AND FUTURE PERSPECTIVES -- CONFLICT OF INTEREST -- FUNDING -- ACKNOWLEDGMENTS -- REFERENCES -- At the Crossroad between Neuronal Hyperexcitability and Neuroinflammation: New Therapeutic Opportunities for Alzheimer's Disease? -- INTRODUCTION -- 1. BACKGROUND ON AD -- 1.1. APP Processing -- 1.2. Genetics of AD -- 1.3. Clinical Trials & -- Treatment Strategies -- 2. PRECLINICAL AVENUES -- 2.1. Neuroinflammation & -- Tumor Necrosis Factor- -- 2.2. Network Hyperexcitability -- 3. CROSS-TALK BETWEEN SYNAPTIC HYPEREXCITABILITY & -- TNF -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- FUNDING -- REFERENCES -- Treatment of Diabetic Neuropathy - Current Possibilities and Perspectives -- INTRODUCTION -- DIABETES MELLITUS -- CHRONIC COMPLICATIONS OF DIABETES MELLITUS -- DIABETIC NEUROPATHY -- ETIOPATHOGENESIS OF DIABETIC NEUROPATHY -- Advanced Glycation End Products -- Oxidative Stress -- Gene Polymorphisms Of Antioxidant Enzymes And Chronic Diabetic Complications. Polyol Pathway -- Protein Kinase C -- Hexosamine Pathway -- Low C-peptide Concentration -- Proinflammatory Cytokines -- Neurotrophic Factors -- Angiotensin-converting Enzyme -- Kinin B1 Receptor -- TREATMENT OF DIABETIC NEUROPATHY -- Treatment of Diabetes Mellitus - Adequate Compensation -- Supportive and Additional Treatment -- Alpha-lipoic Acid -- Symptomatic Treatment -- Treatment in Experimental and Clinical Studies -- Anti-inflammatory Drugs -- Neurotrophic Factors -- Angiotensin Converting enzyme (ACE) Inhibitors -- Novel Drugs with Antioxidant Functions -- Non-pharmacological Therapy -- inhibitors of Epigenetic Modifications -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- The Now and Tomorrow of Migraine Treatments -- INTRODUCTION -- PATHOPHYSIOLOGICAL OVERVIEW -- ACUTE ATTACK TREATMENT -- Currently Available Drugs -- Nonsteroidal Anti-inflammatory Drugs (NSAIDs) -- Ergot Alkaloids and Triptans -- Combination Regimens -- Narcotic Analgesics -- Hyperbaric Oxygen Therapy -- Medication Overuse Headache -- Novel Targets for Attack Treatment -- CGRP -- NOS Inhibition -- TRP Channels -- Glutamate Receptors -- PACAP-38 -- Cannabinoids -- The Parenchymal Inflammatory Cascade -- PROPHYLACTIC TREATMENT -- Currently Available Drugs -- Antiepileptics -- Antidepressants -- Beta Blockers -- Calcium Channel Blockers -- Glutamate Receptor Antagonists --

Triptans -- Novel Targets for Prophylactic Treatment -- CGRP -- NOS
Inhibition -- Gap Junction Blockers -- Renin-Angiotensin System --
Acid Sensing Ion Channels -- Botulinum Neurotoxin -- CONCLUDING
REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS --
REFERENCES -- The Now and Tomorrow of Ischemic Stroke Treatment
-- ADVANCES IN TREATMENT OF ACUTE ISCHEMIC STROKE --
Recanalization/Reperfusion -- Neuro-Glial Protection -- Prevention of
Secondary Complications.
ADVANCES IN SECONDARY PROPHYLAXIS OF ISCHEMIC STROKE --
CONCLUDING REMARKS -- CONFLICT OF INTEREST --
ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX.
